What's in Kowa Research Institute, Inc.'s pipeline?

Kowa Research Institute, Inc. has 6 drugs in our index: 2 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Kowa Research Institute, Inc.'s portfolio?

Top competitors by shared drug class: Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical Company Limited, Beijing Tiantan Hospital, Abbott, Daewoong Pharmaceutical Co. LTD..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kowa-research-institute-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Kowa Research Institute, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kowa Research Institute, Inc. pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
Pitavastatin (NK-104)	Pitavastatin (NK-104)	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
K-161	K-161	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Placebo (for K-877)	Placebo (for K-877)	phase 3

Therapeutic area mix

Cardiovascular · 1
Diabetes · 1
Infectious Disease · 1
Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chong Kun Dang Pharmaceutical · 2 shared drug classes
Hanmi Pharmaceutical Company Limited · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Abbott · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
AstraZeneca · 2 shared drug classes
JW Pharmaceutical · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Kowa Research Institute, Inc.:

Cite this brief

Drug Landscape (2026). Kowa Research Institute, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kowa-research-institute-inc. Accessed 2026-05-17.